Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Ascelia Pharma AB ( (SE:ACE) ) is now available.
Ascelia Pharma’s Board of Directors has decided to convert 53,335 series C shares into ordinary shares to fulfill obligations under a performance-based share saving program. This conversion is part of the company’s long-term incentive program, with shares allocated to the CEO and other participants, maintaining the total number of outstanding shares at 127,902,580. This move reflects Ascelia Pharma’s commitment to incentivizing key personnel, potentially enhancing its strategic positioning in the biotech industry.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs that address unmet medical needs. The company is based in Malmö, Sweden, and is publicly traded on Nasdaq Stockholm under the ticker ACE. Its current drug candidates in development are Orviglance and Oncoral.
Average Trading Volume: 1,579,947
Technical Sentiment Signal: Sell
Current Market Cap: SEK363.3M
For an in-depth examination of ACE stock, go to TipRanks’ Overview page.